Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cerecor, Inc.
Kyorin, Eisai build on earlier OAB deal to team on vibegron. Plus deals involving Piramal/Hemmo, ImmuneOncia/3D Medicines, Kyowa Kirin/Cerecor, Simcere/Kazia, Nippon Shinyaku/Menarini, Tarsus/LianBio
Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.
Tris acquires Pfizer subsidiary Nextwave, which developed pair of ADHD drugs using Tris delivery technology. Lilly gets oral CGRP candidate from Chugai, while Dova signs US co-promotion partner for Doptelet.
Already a significant investor in the health care technology firm, buyout will give Roche access to substantial real-world cancer development data. Astellas acquires stem cell-focused Universal Cells.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Ichorion Therapeutics, Inc.
- Trx Pharmaceuticals, LLC
- Zylera Phamaceuticals, LLC
- Aevi Genomic Medicine, Inc.